Showing 631-640 of 4078 results for "".
On New Therapeutics and Real Sushi
https://practicaldermatology.com/series/the-practical-dermatology-podcast/on-new-therapeutics-and-real-sushi/32849/The latest news and updates, plus E. James Song, MD, FAAD, joins Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, to discuss the 2025 outlook for new therapeutics and play "Two Truths and a Lie." Dr. Song says he has been a wrestler, a jazz musician, and a sushi chePractical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 5
https://practicaldermatology.com/programs/practical-dermatology/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-5/32903/Host Neal Bhatia, MD, FAAD, and guests Jason E. Hawkes, MD, MS, FAAD, and Laura K. Ferris, MD, PhD, FAAD, discuss getting clinicians out of the mindset of using traditional IL-17 and IL-23 blockers for generalized pustular psoriasis, understanding that it is a chronic disease that needs a chronic trMental Health Implications in Psoriasis
https://practicaldermatology.com/programs/practical-dermatology-il-17-journal-club/mental-health-implications-in-psoriasis/48771/Andrew Blauvelt, MD, MBA, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to talk about how IL-17 inhibition can reduce suicidal ideation and behavior in psoriasis patients, as covered in the Journal of the American Academy of Dermatology article “Mental health outcomes in paUnderstanding the Effect of Targeting IL-17A/F in Psoriatic Arthritis
https://practicaldermatology.com/programs/practical-dermatology-il-17-journal-club/understanding-the-effect-of-targeting-il-17af-in-psoriatic-arthritis/56663/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Naeim T. Issa, MD, PhD, FAAD, continue their discussion of the Mediterranean Journal of Rheumatology article “Emerging Targets in Psoriatic Arthritis: Dual IL-17A/F and Selective TYK2 Inhibition in a Clinical Perspective,” focusinFDA Approves Axillary Hyperhidrosis Treatment; Study Examines Biologic Outcomes in Psoriasis
https://practicaldermatology.com/series/dermwire-tv/fda-approves-axillary-hyperhidrosis-treatment-study-examines-biologic-outcomes-psoriasis/26562/In this week's DermwireTV, the FDA approves a first-of-its-kind gel for axillary hyperhidrosis; a new analysis examines how smoking, BMI, and age affect biologic outcomes in psoriasis; and the CEO of Aerolase joins us to discuss the latest trends in the aesthetic laser market.PDT in Action: New Options for Actinic Keratosis
https://practicaldermatology.com/series/pdt-in-practice/pdt-in-action-new-options-for-actinic-keratosis/20210/Dr. Joel L. Cohen, a board-certified dermatologist practicing in Denver, shares insights into the use of photodynamic therapy (PDT) in his practice and how PDT has impacted the options for the treatment of actinic keratosis.Photoprotection in Diverse Patient Populations
https://practicaldermatology.com/programs/practical-dermatology/photoprotection-in-diverse-patient-populations/18196/In part one of a three-part podcast series on dermatologic issues facing patients with darker skin tones, Drs. Andrew Alexis, Corey Hartman, and Janiene Luke discuss photoprotection and why it matters for all patients.The Use of Lasers and Energy-Based Devices in Patients with Richly Pigmented Skin
https://practicaldermatology.com/programs/practical-dermatology/the-use-of-lasers-and-energy-based-devices-in-patients-with-richly-pigmented-skin/18199/In the last of a three-part podcast series on dermatologic issues facing patients with darker skin tones, Andrew Alexis, MD, a dermatologist from New York City and the President of the Skin of Color Society, Corey Hartman, MD, a dermatologist in Birmingham, Alabama, and Janiene Luke, MD, a dermatoloClosing Gaps in Care for People of Color with Psoriatic Disease
https://practicaldermatology.com/programs/practical-dermatology/closing-gaps-in-care-for-people-of-color-with-psoriatic-disease/18190/Black, Hispanic, Asian, and other people of color with plaque psoriasis and psoriatic arthritis often face delayed diagnosis, misdiagnosis, and limited access to testing, treatment, and care. Determi-Nation, a new initiative sponsored by Janssen Pharmaceuticals, aims to change this. Patient advocateNon-Biologics in Treatment and Management of Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/non-biologics-in-treatment-and-management-of-prurigo-nodularis/48785/James Q. Del Rosso, DO, FAOCD, discusses the utility of topical therapies, cleansers, moisturizers, and phototherapy in treatment and management of prurigo nodularis.